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ers do not suffer from this limitation and gene expression proﬁling of 
resected lung cancer also is feasible on a large scale.
In summary the future of lung cancer treatment rests with studies which 
are based on appropriately selected patient populations. Through this 
process we hope to learn more about mechanisms of resistance to our 
established drugs and to uncover new targets on which to base novel 
therapies. 
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Recent advances in molecular biology have led to the development of 
a myriad of anticancer agents that speciﬁcally target aberrant path-
ways and other proteins that are relatively speciﬁc for tumor cells. 
These targets can be broadly classiﬁed as tumor stroma (blood and 
lymphatic vessels and other connective tissues), cell cycle regulation, 
cell signaling and cell death elements. A variety of approaches have 
been tested, all aimed at target inhibition to date. The most commonly 
used, and validated currently are pharmacologic interventions using 
small molecule inhibitors and monoclonal antibodies. As anti-cancer 
therapeutics with distinct targeting capabilities against malignant cells 
become available for clinical evaluation, several critical issues in drug 
development need to be addressed. Because many novel agents are 
often cytostatic (rather than cytocidal) it is felt that objective response 
rates by RECIST or WHO criteria may not be the most appropriate 
endpoint for the development of these agents. However it’s unclear as 
to approaches that should be used. One suggestion is the measurement 
of tumor size in a dynamic fashion so that different levels of shrinkage 
can be quantiﬁed. This approach is exempliﬁed by the popularity of 
“waterfall diagrams” as have been used for sorafenib, sunitinib, axitinib 
and a number of small molecule inhibitors of angiogenic signaling. The 
utilization of randomized phase II studies with a standard control arm 
that allows investigators to discern the effects of growth stasis indepen-
dent of tumor biology has also being suggested as has designs such as 
the randomized discontinuation design. These approaches and several 
others will be discussed.
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Getting funded for research is crucial to those in academia and impor-
tant for researchers in most settings. Granting agencies include govern-
ment institutes, nongovernmental foundations and agencies, industry, 
even your own institution! Regardless of the granting agency, several 
principles are crucial (assuming you have a good idea!):
• Follow the instructions!
• Write and rewrite
• Have others read
• Have clear and clearly achievable aims
• Demonstrate credibility with preliminary work
• Demonstrate knowledge of the work of others
• Provide sufﬁcient detail to gain conﬁdence of reviewers
• Try, try again!
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Early detection of lung cancer: where we are going?
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Despite concerted efforts, global consumption of cigarettes remains 
high and will predictably lead to signiﬁcant adverse health outcomes in 
subsequent decades. Even in the setting of a heavy smoker, who does 
stop smoking, their risk of lung cancer never returns to normal. Many 
lung cancers are now occurring in former smokers and so improving 
early detection has the potential of adding to the public health beneﬁt 
of smoking cessation. 
Recent reports from research groups in New York, Milan and Japan 
suggest that outcomes from lung cancer screening can be associated 
with a high frequency of detecting Stage I lung cancer. These cases 
are generally found efﬁciently using deﬁned diagnostic algorithm at 
baseline and work up efﬁciency can be further improved in evaluating 
annual follow up cases. To develop a real public health tool for efﬁcient 
and effective early lung cancer detection in high risk groups, this tool 
has to be optimized to allow robust performance in a variety of real 
world settings. This an important challenge as the resolution and ca-
pabilities of imaging tools such as spiral CT has improved rapidly and 
this quick pace of evolution has consistent impact on the subsequent 
downstream clinical management 
From a public health perspective, the efﬁciency of case work up should 
be high with minimal use of invasive testing to minimize the cost and 
morbidity of lung cancer screening. International cooperation in shar-
ing the results of such researcher is critical to making rapid progress in 
this promising new area. A number of randomized evaluations of lung 
cancer screening are ongoing but the results of these trials are not ex-
pected for some years. At this meeting, a number of new approaches for 
managing early lung cancer with innovative surgical approaches will be 
discussed. As with other cancer screening efforts, there is a need to de-
ﬁne the least expensive and morbid management to achieve favorable 
mortality reduction. This effort to reduce potential “over treatment” is 
a critical research direction in achieving a more favorable balance of 
risks and beneﬁts in the application of lung cancer screening strategies. 
